Adjuvant discovery for vaccines and for autoimmune and allergic diseases
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00054
- Awardee
-
Inimmune Corp UEI EF8AMXMGG8W5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $598,808
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · PHS20211 · Posted Jul 9, 2020
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Solicitation · Posted Jul 28, 2020
- Contract value 100% obligated
- $598,808.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Missoula, MT 59802, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $598,808 |
About this award
This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received several previous SBIR awards from NIAID for related work, such as developing a synthetic AS01-like adjuvant system for influenza vaccines and a Toll-like receptor 4 agonist treatment for allergic rhinitis. This contract award is part of a broader SBIR solicitation released by NIH and the Centers for Disease Control and Prevention (CDC) seeking innovative small business research proposals across a range of biomedical and public health topics.
Quick answers
Who was awarded contract 75N93021C00054?
75N93021C00054 was awarded to Inimmune Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2021.
How much is contract 75N93021C00054 worth?
The government has obligated $598,808 on 75N93021C00054.
Was contract 75N93021C00054 competed?
The extent of competition for 75N93021C00054 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award